Bioequivalence of Nilotinib 200 mg Capsules in Healthy Participants Under Fasting Conditions.

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-514448-10-00

Acronym

BLCL-NIL-FDA-02

Enrollment

Registered

2024-07-12

Start date

2024-08-09

Completion date

2024-09-27

Last updated

2024-07-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

No medical condition.

None listed

Sex/Gender

All

Age

18 Years to 64 Years

Portugal

None listed

Source: EU CTIS · Data processed: Feb 4, 2026